Skip to content
lifestyle.ebusinessplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Replimune, Inc.
Replimune Announces Pricing of $150 Million Underwritten Offering
August 10, 2026
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
August 6, 2026
Replimune Announces Favorable Outcome of FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
July 30, 2026
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026
Replimune to Present at Two Upcoming Investor Conferences
March 11, 2026